

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10589907
Filing Date	2007-06-29
First Named Inventor	Heike Gielen-Haertwig
Art Unit	1624
Examiner Name	Emily B. Bernhardt
Attorney Docket Number	BHC 041035

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7893073		2011-02-22	Gielen-Haertwig, et al.	
	2	7199136		2007-04-03	Gielen-Haertwig, et al.	
	3	7687510		2010-03-30	Gielen-Haertwig, et al.	
	4	5532366		1996-07-02	Edwards, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20100184788		2010-07-22	Gielen-Haretwig, et al.	
	2	20080045541		2008-02-21	Gielen-Haertwig, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS						Remove

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10589907
Filing Date	2007-06-29
First Named Inventor	Heike Gielen-Haertwig
Art Unit	1624
Examiner Name	Emily B. Bernhardt
Attorney Docket Number	BHC 041035

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	05037799	WO	A1	2005-04-28	Cytokinetics, Inc.		<input type="checkbox"/>
	2	05082864	WO	A2	2005-09-09	Bayer Healthcare AG		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

[Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Namazi, et al., "Investigation the Chemical Reactivity of Positions N-3, C-5 and C6-Methyl Group in Biginelli Type Compounds and Synthesis of New Dihydropyrimidine Derivatives," J. Heterocyclic Chem., 38: 1051-1054 (2001)	<input type="checkbox"/>
	2	Ohmoto, et al., "Development of Orally Active Nonpeptidic Inhibitors of Human Neutrophil Elastase," J. Med. Chem. 44 pp. 1268-1285 (2001)	<input type="checkbox"/>
	3	Palomo et al. "Preparation of 3-Alkyl beta-Lactams via the Ketene-Imine Cycloaddition Reaction Using alpha-(Phenylthio)alkanoyl Halides as Starting Materials: Application to the Synthesis of (+/-)-Carbapenem Building Blocks and Related Compounds," J. Org. Chem. 56:4418-4428 (1991)	<input type="checkbox"/>
	4	Walker et al. "Strategies for the Inhibition of Serine Proteases," CMLS, Cell. Mol. Life Sci. 58: 596-624 (2001)	<input type="checkbox"/>
	5	Abbenante et al. "Protease Inhibitors in the Clinic," Medicinal Chemistry, 1:71-104 (2005)	<input type="checkbox"/>
	6	Chughtai et al. "Potential Role of Inhibitors of Neutrophil Elastase in Treating Diseases of the Airway," Journal of Aerosol Medicine, 17(4): 289-298 (2004)	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.B./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10589907
Filing Date	2007-06-29
First Named Inventor	Heike Gielen-Haertwig
Art Unit	1624
Examiner Name	Emily B. Bernhardt
Attorney Docket Number	BHC 041035

	7	Ulrich, Chapter 4: Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, August 2002 (7 pages provided)	<input type="checkbox"/>
	8	Roghanian, et al., "Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase," Am. J. of Respiratory and Critical Care Medicine, 174:1189-1109 (2006)	<input type="checkbox"/>
	9	Hsieh, et al., "The evaluation and structure-activity relationships of 2-benzolaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents," Bioorganic & Med. Chem. Lett., 17:1812-1817 (2007)	<input type="checkbox"/>
	10	Kyne, et al., "The evaluation of structure-activity relationships of 2-benzoylamino benzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents," Am. Heart J., 139(1): 94-100, (2000)	<input type="checkbox"/>
	11	Lewandowski, et al., "A combinatorial approach to recognition of chirality: preparation of highly enantioselective aryl-dihydropyrimidine selectors for chiral HPLC," J. Comb. Chem., 1:105-112 (1999).	<input type="checkbox"/>
	12	Pending US patent application serial no. 10/590,770, filed 6/18/2007. Published as US2008-0064704, cited above.	<input type="checkbox"/>
	13	Pending US patent application serial no. 12/633,723, filed 12/8/2009. Published as US2010-0814788, cited above.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

**EXAMINER SIGNATURE**

Examiner Signature	/Emily Bernhardt/	Date Considered	09/09/2011
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

NOTE: Ohmoto and Kyne references not seen in file but were obtained by examiner.